HSD17B13 Antibody - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] -

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded human liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] -

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded rat liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] -

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded mouse liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

HSD17B13 promotes the accumulation of intracellular lipid droplets and causes hepatocyte injury. (A) mRNAs in palmitate-treated cells were measured by qRT-PCR. (B) Schematic of full-length or truncated transcripts of HSD17B13. (C) Representative confocal images of L02 cells transfected with His-tagged HSD17B13 transcripts (red) and LDs (green) after being induced by OA (400 μM) for 24 h. Nuclei were labeled with DAPI (blue). (D,E) Representative immunofluorescence staining images for LDs (red) (D) and relative intracellular Nile red positive areas were quantified (E) in L02 cells transfected with HSD17B13 transcripts after OA (400 μM) challenge for 24 h, the slides were counterstained with DAPI. (F) Schematic of the experimental design for investigating the effect of HSD17B13 on intracellular TGs, the contents of TGs were detected and the half-life of TGs was calculated. (G,H) Levels of ALT (G) and AST (H) in supernatants and cell lysates of Huh7 cells transfected with the plasmids of HSD17B13 for 24 h. (I) mRNA of proinflammatory markers in L02 cells transfected with plasmids of HSD17B13 for 24 h. Results are expressed as mean +/- SEM. OA, oleic acid; LDs, lipid droplets; TGs, triglycerides; PLIN2, perilipin 2; ALT, alanine transaminase; AST, aspartate transaminase; TGF-beta 1, transforming growth factor-beta 1; IL-6, interleukin 6; CXCL3, C-X-C motif chemokine ligand 3. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

Higher HSD17B13 expression is mainly in hepatocytes and directly induced by etiological agents. (A,B) Protein (A) and mRNA (B) were detected in mouse primary cells. (C) Liver samples from NAFLD mice induced by HFD, BDL, CCl4, and MCD were processed with immunofluorescence co-staining for HSD17B13 with ALB (hepatocyte marker), CD31 (endothelial marker), alpha-SMA (activated HSC marker), or CD11b (macrophage marker). Slides were counterstained with DAPI (Scale bars, 50 μm). (D) L02 cells were treated by palmitate, OA, CCl4 lipopolysaccharide, or TGF-beta 1 for 24 h, mRNA was measured by qRT-PCR. (E,F) Huh7.5 cells were infected with HCV, RNAs were measured by qRT-PCR (E), and proteins were measured by Western blotting (F) at 72 h. (G) Huh7.5 cells were infected by HCV (MOI = 0.1) and mRNA was measured by qRT-PCR at designated days post-infection. (H) mRNA in respective host cells infected by HCV, H1N1 and EV71 was measured by qRT-PCR. Results are expressed as mean +/- SEM. HSCs, hepatic stellate cells; KCs, Kupffer cells; LSECs, liver sinusoidal endothelial cells; PHs, hepatic parenchymal cells; HFD, high-fat diet; BDL, bile-duct ligation; CCl4, carbon tetrachloride; MCD, methionine-choline-deficient diet; OA, oleic acid; TGF-beta 1, transforming growth factor-beta 1; MOI, multiplicity of infection; HCV, hepatitis C virus; H1N1, influenza A virus; EV71, enterovirus type 71. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean +/- SEM. (scale bars, 50 μm). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl4, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean +/- SEM. (scale bars, 50 μm). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl4, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

HSD17B13 promotes the accumulation of intracellular lipid droplets and causes hepatocyte injury. (A) mRNAs in palmitate-treated cells were measured by qRT-PCR. (B) Schematic of full-length or truncated transcripts of HSD17B13. (C) Representative confocal images of L02 cells transfected with His-tagged HSD17B13 transcripts (red) and LDs (green) after being induced by OA (400 μM) for 24 h. Nuclei were labeled with DAPI (blue). (D,E) Representative immunofluorescence staining images for LDs (red) (D) and relative intracellular Nile red positive areas were quantified (E) in L02 cells transfected with HSD17B13 transcripts after OA (400 μM) challenge for 24 h, the slides were counterstained with DAPI. (F) Schematic of the experimental design for investigating the effect of HSD17B13 on intracellular TGs, the contents of TGs were detected and the half-life of TGs was calculated. (G,H) Levels of ALT (G) and AST (H) in supernatants and cell lysates of Huh7 cells transfected with the plasmids of HSD17B13 for 24 h. (I) mRNA of proinflammatory markers in L02 cells transfected with plasmids of HSD17B13 for 24 h. Results are expressed as mean +/- SEM. OA, oleic acid; LDs, lipid droplets; TGs, triglycerides; PLIN2, perilipin 2; ALT, alanine transaminase; AST, aspartate transaminase; TGF-beta 1, transforming growth factor-beta 1; IL-6, interleukin 6; CXCL3, C-X-C motif chemokine ligand 3. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HSD17B13 Antibody - Azide and BSA Free [NBP3-04837] -

HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean +/- SEM. (scale bars, 50 μm). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl4, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35628360), licensed under a CC-BY license. Not internally tested by Novus Biologicals.